Atea Pharmaceuticals financials
$5.18−0.38%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY17 Dec 31 | FY16 Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $351.4M | $48.6M | $5.8M | $9.3M |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $351.4M | $48.6M | $5.8M | $9.3M |
| Gross margin | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$180.9M | -$192.9M | -$164.2M | -$130.7M | $138.4M | -$11.0M | -$10.0M | -$25.0M |
| Net income | -$158.3M | -$168.4M | -$136.0M | -$115.9M | $121.2M | -$10.9M | -$12.5M | -$25.4M |
| Net margin | — | — | — | — | 34.5% | −22.5% | −213.4% | −273.1% |
| Diluted EPS | $-1.94 | $-2.00 | $-1.63 | $-1.39 | $1.37 | $-0.51 | $-91.65 | $-7.26 |
| EBITDA | -$180.5M | -$192.5M | -$163.7M | -$130.4M | $138.4M | -$11.0M | -$9.6M | -$24.9M |
| Operating cash flow | -$132.0M | -$135.5M | -$85.4M | -$121.0M | -$87.0M | $296.7M | -$10.0M | -$14.1M |
| Free cash flow | -$132.0M | -$135.5M | -$85.4M | -$122.9M | -$87.0M | $296.7M | -$10.2M | -$14.3M |
| Diluted shares | 81.5M | 84.3M | 83.4M | 83.2M | 88.2M | 21.6M | 0.1M | 3.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $95.7M | $64.7M | $143.8M | $188.5M | $764.4M | $850.1M |
| Short-term investments | $206.1M | $390.0M | $434.3M | $458.2M | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $315.2M | $464.7M | $595.0M | $666.7M | $772.9M | $863.6M |
| Total liabilities | $39.8M | $25.8M | $39.8M | $26.1M | $62.8M | $315.8M |
| Shareholders' equity | $275.4M | $438.9M | $555.2M | $640.6M | $710.1M | $547.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology